A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This non-randomized, multi-center, open-label study will evaluate the pharmacokinetics and
the safety and tolerability of danoprevir (RO5190591) and ritonavir in healthy volunteers and
patients with mild, moderate or severe hepatic impairment. Participants will be administered
repeated daily doses of danoprevir and ritonavir. The anticipated time on study treatment is
10 days.